Inoperable Early Stage Non-small Cell Lung Cancer
Conditions
Keywords
inoperable early stage non-small cell lung cancer, radiation therapy
Brief summary
Surgical resection with mediastinal lymph node sampling is currently the therapy of choice for early stage (I-II) non-small cell lung cancer (NSCLC). Selected patients unwilling or unable to tolerate surgery are referred for so-called 'curative' high dose radiotherapy. This has shown to result in a long term local disease control rate and a high cancer specific survival. The current trial addresses the issue if progression free survival (PFS) in patients treated with radiotherapy can be predicted by a multi-variate model derived from a composite of bio-imaging and biomarkers
Interventions
RADIATIONhypofractionated radiation therapy
hypofractionated radiation therapy
Sponsors
Nationaal Kankerplan
University Hospital, Ghent
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Proof of cT1a/b - 2a/b N0M0 NSCLC * Informed Consent signed * Resectable tumour * \> 18 years old * men and women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| development and validation of a multi-variate predictive model | from 2 to 5 years | To develop and validate a multi-variate predictive model based on bio-imaging and biomarkers for progression)free survival from 2 to 5 years. |
Secondary
| Measure | Time frame |
|---|---|
| the clinical response and complication rate | from 2 to 5 years |
| local, regional or distant failure | from 2 to 5 years |
| progression free survival | from 2 to 5 years |
| disease specific overall survival | from 2 to 5 years |
Countries
Belgium
Outcome results
None listed